Medikabazaar Partners With Korea’s Boditech Med Inc. For Range Of COVID-19 And Other Diagnostic Solutions

Medikabazaar, India’s leading B2B Healthtech platform, today announced its partnership with Boditech Med Inc., a leading Korea-based Point of Care testing and In-Vitro diagnostic company. This would be an exclusive collaboration with Medikabazaar distributing Boditech's path-breaking In-Vitro Diagnostic Solutions using its extensive network. The partnership would see Medikabazaar distributing Boditech’s automated desktop analyzers such as the AFIAS 1 and AFIAS 6 immunoassay analyzers with a range of reagents and diagnostic kits. These will provide diagnosis of COVID-19 as well as diagnostic solutions for cardiac, cancer, diabetes, hormonal and other infections such as dengue, rota and adenovirus.

Mr. Vivek Tiwari, Founder & CEO, Medikabazaar said, “With this partnership, we would be able to provide access to quality Point of Care testing to all corners of India, thus contributing to significantly improving the nation's testing and diagnostic ecosystem. Even as we emerge from the second wave of the COVID pandemic, it is necessary for us to take all precautions to prevent any surge and point of care testing will help in making rapid clinical decisions for monitoring, treatment and making operational decisions as to allocation of resources. Point of care testing saves time and leads to long term societal and economic benefits. At Medikabazaar, this partnership with Boditech will bolster our diagnostics portfolio to support pathology services.”

Mr. ALN Prasad, Managing Director, Boditech Med India said: “AFIAS Point-of-care testing is a one-of-its-kind diagnostic solution that maximizes user convenience by offering a wide range of immunological test parameters, just with a finger-prick based sample. It enables physicians to perform tests within the clinic or hospital and helps them to make quick decisions to undertake evidence-based treatments, which proves crucial in critical care facilities where immediate test results are essential. Testing and diagnostic facilities are highly centralised in India, and with our collaboration with Medikabazaar, we are looking to achieve decentralisation of testing facilities and reach the remotest corners of the country. With Medikabazaar’s extensive reach in tier-II, III and IV cities, more than 1.5 Lakh medical practitioners and over 50,000 medical establishments will benefit from AFIAS’s high-speed results."

The AFIAS-1 is a compact immunoassay analyzer with the all-in-one cartridge system. It has a single channel lateral flow immunoassay platform and uses

disposable cartridges that include all the reagents necessary for the test. Small, compact and light, it offers ease of use with proprietary C-tips for fingertip blood and quick test results with reliability. 

The AFIAS-6 is an automated Immunoassay Analyzer with the all-in-one cartridge system that is uniquely integrated sample-to-answer system. It allows 6 parallel tests of differing parameters with fast turn-around and high sensitivity rivaling those of the full-featured systems in commercial labs. It is US FDA 510(K) cleared.

About Medikabazaar:

Medikabazaar is India's pioneering and largest online B2B Healthcare platform for medical supplies. Founded in 2015 by Vivek Tiwari and Ketan Malkan, the company has been growing exponentially and is now clearly the most prominent digital healthtech platform in India's medical procurement and supply chain industry.

It started with a simple idea to help improve Indian healthcare by making it accessible and affordable. The company devised a website coupled with additional value-added services via which medical establishments can search for their required supplies, order them at the right prices and time, and receive them at their doorsteps irrespective of their location.